Literature DB >> 8943066

BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.

T Strobel1, L Swanson, S Korsmeyer, S A Cannistra.   

Abstract

To investigate the role of BAX in chemotherapy-induced apoptosis, we transfected the SW626 human ovarian cancer cell line, which lacks functional p53, with a cDNA encoding for murine BAX. Immunoblotting revealed that BAX transfectants expressed a mean of 10-fold increased levels of BAX compared with neo-transfected control clones, with similar levels of BCL-2 and BCL-xL. The cytotoxicity of paclitaxel, vincristine, and doxorubicin was significantly enhanced in BAX transfectants compared with control clones, whereas the cytotoxicity profile of carboplatin, etoposide, and hydroxyurea was unchanged. Increased paclitaxel-induced cytotoxicity of BAX clones was associated with enhanced apoptosis, as assessed by morphologic and flow cytometric criteria. These data suggest that sufficient levels of BAX may bypass the need for upstream molecules such as p53 in the process of chemotherapy-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943066      PMCID: PMC19500          DOI: 10.1073/pnas.93.24.14094

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation.

Authors:  E Falcieri; A M Martelli; R Bareggi; A Cataldi; L Cocco
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

2.  The biology of cell death in tumours.

Authors:  A H Wyllie
Journal:  Anticancer Res       Date:  1985 Jan-Feb       Impact factor: 2.480

3.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.

Authors:  T Miyashita; S Krajewski; M Krajewska; H G Wang; H K Lin; D A Liebermann; B Hoffman; J C Reed
Journal:  Oncogene       Date:  1994-06       Impact factor: 9.867

Review 4.  Features of apoptotic cells measured by flow cytometry.

Authors:  Z Darzynkiewicz; S Bruno; G Del Bino; W Gorczyca; M A Hotz; P Lassota; F Traganos
Journal:  Cytometry       Date:  1992

5.  Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.

Authors:  K Bhalla; A M Ibrado; E Tourkina; C Tang; M E Mahoney; Y Huang
Journal:  Leukemia       Date:  1993-04       Impact factor: 11.528

6.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.

Authors:  E Yonish-Rouach; D Resnitzky; J Lotem; L Sachs; A Kimchi; M Oren
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

7.  Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein.

Authors:  R J Arceci; K Stieglitz; J Bras; A Schinkel; F Baas; J Croop
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

8.  mdm2 expression is induced by wild type p53 activity.

Authors:  Y Barak; T Juven; R Haffner; M Oren
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

9.  Cell nucleus and DNA fragmentation are not required for apoptosis.

Authors:  K Schulze-Osthoff; H Walczak; W Dröge; P H Krammer
Journal:  J Cell Biol       Date:  1994-10       Impact factor: 10.539

Review 10.  Bcl-2 and the regulation of programmed cell death.

Authors:  J C Reed
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

View more
  40 in total

1.  Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.

Authors:  P De Feudis; S Vignati; C Rossi; T Mincioni; R Giavazzi; M D'Incalci; M Broggini
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

3.  Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking.

Authors:  P Scheipers; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

4.  Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP.

Authors:  Beata Kosmider; Izabela Wojcik; Regina Osiecka; Jacek Bartkowiak; Elzbieta Zyner; Justyn Ochocki; Pawel Liberski
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 5.  Direct Activation of Bax Protein for Cancer Therapy.

Authors:  Zhiqing Liu; Ye Ding; Na Ye; Christopher Wild; Haiying Chen; Jia Zhou
Journal:  Med Res Rev       Date:  2015-09-23       Impact factor: 12.944

6.  Pro-apoptotic activity of imidazole derivatives mediated by up-regulation of Bax and activation of CAD in Ehrlich Ascites Tumor cells.

Authors:  C Anil Kumar; Shankar Jayarama; Bharathi P Salimath; Kanchugarakoppal S Rangappa
Journal:  Invest New Drugs       Date:  2007-03-20       Impact factor: 3.850

Review 7.  Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer.

Authors:  W Brian Dalton; Vincent W Yang
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

8.  A natural compound from Hydnophytum formicarium induces apoptosis of MCF-7 cells via up-regulation of Bax.

Authors:  Judit Hohmann; Hasmah Abdullah; Azimahtol Hawariah Lope Pihie; Joseph Molnár
Journal:  Cancer Cell Int       Date:  2010-05-04       Impact factor: 5.722

Review 9.  Caspase inhibitors for the treatment of hepatitis C.

Authors:  Howard C Masuoka; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

10.  A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells.

Authors:  Yi Huang; Erin R Hager; Dawn L Phillips; Valerie R Dunn; Amy Hacker; Benjamin Frydman; John A Kink; Aldonia L Valasinas; Venodhar K Reddy; Laurence J Marton; Robert A Casero; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.